Detail of "171099-57-3"

Reference

In vitro activity and spectrum of LY333328, a novel glycopeptide derivative

In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. Jones, Ronald N.; Barrett, Mary S.; Erwin, Meridith E. (Dep. Pathol., Univ. Iowa Coll. Med., Iowa City, IA, USA). Antimicrobial Agents and Chemotherapy, 41(2), 488-493 (English) 1997 American Society for Microbiology. CODEN: AMACCQ. ISSN: 0066-4804. DOCUMENT TYPE: Journal CA Section: 10 (Microbial, Algal, and Fungal Biochemistry) Ref. methods were used to det. the potency of LY333328, a semisynthetic glycopeptide deriv. with a key N-alkylation substitution, against 833 strains (393 gram-pos. strains and representative gram-neg. bacilli) with various defined resistance mechanisms. The MICs at which 90% of the isolates are inhibited (MIC90s, in mg/mL) of LY333328 and the percentages of strains inhibited at ￡8 mg/mL were as follows: for oxacillin-susceptible Staphylococcus aureus, 2 and 100%, and for oxacillin-resistant Staphylococcus aureus, 4 and 100%; for oxacillin-susceptible Staphylococcus epidermis, 4 and 100% and for oxacillin-resistant Staphylococcus aureus, 8 and 96%; for Streptococcus serogroups A, B, C, and G, 0.25-1 and 100%; for Streptococcus pneumoniae, ￡0.015-0.06 and 100%; for Enterococcus faecalis, 2 and 100%; and for vancomycin-susceptible Enterococcus faecium, 0.25 and 100%, and for vancomycin-resistant Enterococcus faecium, 4 and 100%. LY333328 was not active (MIC50 316 mg/mL) against >400 representative strains of Enterobacteriaceae, pseudomonads, Acinetobacter spp., Stenotrophomonas maltophilia, Haemophilus influenzae, Moraxella catarrhalis, pathogenic Neisseria spp., and anaerobic gram-neg. bacilli. Gram-pos. anaerobes were LY333328 susceptible (MICs ￡2 mg/mL). 171099-57-3 is just another one chemical used in this study. Test methods and conditions may have affected MICs of LY333328, with most (species variation) agar diln. MICs being greater than the broth microdilution MICs. .

Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose

Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Fetterly, Gerald J.; Ong, Christine M.; Bhavnani, Sujata M.; Loutit, Jeffrey S.; Porter, Steven B.; Morello, Lisa G.; Ambrose, Paul G.; Nicolau, David P. (Cognigen Corporation, Buffalo, NY, USA). Antimicrobial Agents and Chemotherapy, 49(1), 148-152 (English) 2005 American Society for Microbiology. CODEN: AMACCQ. ISSN: 0066-4804. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Oritavancin is a novel glycopeptide currently being developed for the treatment of complicated skin and skin structure infections (cSSSI), including those caused by multidrug resistant gram-pos. pathogens. The disposition of oritavancin in skin structures was investigated using a cantharide-induced blister fluid model. interstitial. Seventeen healthy male subjects received oritavancin, but only 16 subjects were evaluated after one subject discontinued study drug. Each subject (eight per dose group) received 200 mg of oritavancin once a day for 3 days (group A) or 800 mg as one single dose (group B). Group A plasma samples and exudates from blister fluid were collected on days 3, 4, 7, 9, and 12 and on days 3, 4, 7, and 9, resp. Group B samples and exudates were collected on days 1, 2, 5, 7, and 10 and on days 1, 2, 5, and 7, resp. Drug concns. were detd.In this article, certain chemicals are used. One of their cas registry numbers is 171099-57-3 using a liq. chromatog.-tandem mass spectrometry assay and, subsequently, pharmacokinetic anal. was performed. Differences between treatment groups in ratios for area under the concn.-time curve for blister fluid and plasma (AUCblister fluid/AUCplasma ratios) were evaluated using a t test (a = 0.05). Mean max. concn. of drug in plasma or blister fluid was approx. 8-fold and 11-fold higher in plasma than in blister fluid following the 200- or 800-mg doses of oritavancin, resp. Mean AUCblister fluid/AUCplasma ratios at 24 h were 0.190 (std. deviation [SD], 0.052) and 0.182 (SD, 0.062) for groups A and B, resp. (P = 0.791). To place these results in a clin. context, mean drug concns. in blister fluid exceed the oritavancin MIC at which 90% of strains are inhibited of Staphylococcus aureus (2 mg/mL) by approx. 2- to 5.5-fold at 12 h and 1.5- to 3-fold at 24 h following administration of both dosing regimes. These results support the potential use of oritavancin for the treatment of cSSSI. .